Viridian Therapeutics, Inc. filed an 8-K reporting a $251.35 million offering of 11,425,000 shares priced at $22 each on October 21, 2025, with an option for underwriters to purchase an additional 1,713,750 shares. This event is significant for the company as it will help fund operations and upcoming projects.